Get the Stockscreener App
4.93
0.80%
-0.06
After Hours:
4.80
-0.13
-2.64%
Traws Pharma Inc stock is traded at $4.93, with a volume of 4,543.
It is down -0.80% in the last 24 hours and up +1.75% over the past month.
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
See More
Previous Close:
$4.99
Open:
$4.96
24h Volume:
4,543
Relative Volume:
0.44
Market Cap:
$15.10M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.50%
1M Performance:
+1.75%
6M Performance:
-69.11%
1Y Performance:
+0.00%
1-Day Range:
$4.82
$5.1299
1-Week Range:
$4.82
$5.96
52-Week Range:
$4.44
$18.22
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| TRAW | 4.93 | 15.10M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Traws Pharma Inc Stock (TRAW) Latest News
Traws Pharma Reports Q3 Financials and Updates on Clinical Advances - MSN
Traws Pharma Faces Uncertain Future Amid Complex Onconova Merger - TipRanks
Traws Pharma Reports Promising Antiviral Drug Progress - TipRanks
Traws Pharma earnings missed by $8.56, revenue topped estimates - Investing.com Canada
Traws Pharma Inc (TRAW) Quarterly 10-Q Report - Quartzy
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results - The Manila Times
Traws Pharma Reports Promising Phase 1 Data Despite Widening Q3 Losses | TRAW Stock News - StockTitan
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update - Marketscreener.com
Traws Pharma regains Nasdaq compliance with bid price - Investing.com India
Traws Pharma regains Nasdaq compliance with bid price By Investing.com - Investing.com UK
Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment - StockTitan
Traws Pharma Inc (TRAW) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges Amid ... - Yahoo Finance
Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil - MyChesCo
Onconova Therapeutics stock hits 52-week low at $4.87 - Investing.com India
Traws Pharma reports positive Phase 1 flu drug results - Investing.com
Traws Pharma reports positive Phase 1 flu drug results By Investing.com - Investing.com Canada
Traws Pharma announces topline Phase 1 data for tivoxavir marboxil - TipRanks
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil - GlobeNewswire
Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil - Marketscreener.com
Onconova Therapeutics stock hits 52-week low at $4.87 By Investing.com - Investing.com Australia
Traws Pharma announces results from its early stage trial for its COVID candidate - MSN
Promising Phase 1 Results for Traws Pharma’s COVID Treatment Candidate - MSN
Traws Pharma reports promising Phase 1 trial for COVID drug - Investing.com
Traws Pharma announces topline Phase 1 results for ratutrelvir - TipRanks
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor - GlobeNewswire
Traws Pharma faces Nasdaq delisting over bid price issue By Investing.com - Investing.com Canada
Traws Pharma faces Nasdaq delisting over bid price issue - Investing.com India
Onconova Therapeutics stock hits 52-week low at $6 - Investing.com India
Onconova Therapeutics stock hits 52-week low at $6 By Investing.com - Investing.com South Africa
Financial Metrics Check: Traws Pharma Inc. (TRAW)’s Ratios for Trailing Twelve Months - The Dwinnex
Traws Pharma Welcomes Luba Greenwood Amid Strategic Board Changes - MyChesCo
Traws Pharma, Inc. Announces Board Changes - Marketscreener.com
Traws Pharma appoints new director, bids farewell to Marino - Investing.com
Was anything positive for Traws Pharma Inc. (TRAW) stock last session? - US Post News
Traws Pharma Appoints Luba Greenwood to Board of Directors - citybiz
Traws Pharma appoints Luba Greenwood to board of directors - TipRanks
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors - GlobeNewswire
Traws Pharma Announces Key Approvals and Reverse Stock Split at 2024 Special Meeting - MSN
Closing Figures Unveiled: Traws Pharma Inc. (TRAW) Drop -10.26, Closes at 0.31 - The Dwinnex
Traws Pharma Inc. (TRAW) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Onconova Therapeutics stock hits 52-week low at $0.32 - Investing.com
Traws Pharma Announces Stock Split, Share Adjustments, and Growth Strategy - TipRanks
Traws Pharma announces results of 2024 Special Meeting of Stockholders - TipRanks
Traws Pharma Inc Stock (TRAW) Financials Data
There is no financial data for Traws Pharma Inc (TRAW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.27%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):